Fig. 4From: A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Bayesian predictive probability of the unfavourable outcome being less than a specific threshold, p1, in a future phase III trial of 500 patients per arm, following various observed proportions of unfavourable outcomes and patient numbers in a STEP trial of equal treatment duration. Solid lines correspond to a sceptical prior and dashed lines to the flat priorBack to article page